Status:
TERMINATED
Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome
Lead Sponsor:
Allergan
Conditions:
Fibromyalgia
Eligibility:
FEMALE
18-75 years
Phase:
PHASE2
Brief Summary
This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with fibromyalgia syndrome. The study is being conducted in 2 parts. Part A enroll...
Eligibility Criteria
Inclusion
- Diagnosis of fibromyalgia syndrome
- Moderate or severe pain associated with fibromyalgia
Exclusion
- Any other uncontrolled disease
- Pregnant or nursing females
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
211 Patients enrolled
Trial Details
Trial ID
NCT00445705
Start Date
March 1 2007
End Date
January 1 2008
Last Update
September 7 2015
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Canton, Ohio, United States
2
Geneva, Switzerland
3
Stanmore, United Kingdom